BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
BioLife Solutions, Inc.NASDAQ: BLFS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.65M rose 20.2% year over year, ahead of the +5.5% change in trailing-twelve-month research & development. Sequentially, it rose 3915.2% from the prior quarter. Over 3 fiscal years it compounded at -20.0% a year.
Context
- Research & development amounted to 7.9% of revenue in FY2025, down 1.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.2% holds above the trailing-twelve-month pace of +5.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.57M USD
- Year-over-year change
- -4.4%
- 4-year CAGR
- -10.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.57M | -4.4% |
| FY2024 | 2024-12-31 | 7.91M | -57.9% |
| FY2023 | 2023-12-31 | 18.8M | +27.0% |
| FY2022 | 2022-12-31 | 14.8M | +25.2% |
| FY2021 | 2021-12-31 | 11.82M | — |
Research & Development vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 research & development of $8.14M is the lowest of the 11 companies compared; the peer median is $38.18M.
- Its year-over-year change of +5.5% is the 6th highest of 11, against a peer median of +4.4%.
- Research & development amounts to 8.2% of revenue for BLFS, versus a peer median of 15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $229.1M | +8.2% | +2.9% | 34.0% | |
| LTM Apr 2026 | $117.98M | -1.9% | +10.0% | 23.8% | |
| LTM Jun 2026 | $96.27M | -10.6% | +16.3% | 16.9% | |
| LTM Jun 2026 | $51.89M | +27.3% | +29.0% | 4378.6% | |
| LTM Apr 2026 | $38.43M | -26.2% | +3.6% | 13.2% | |
| LTM Sep 2026 | $37.92M | +31.1% | +3.7% | 6.1% | |
| LTM Sep 2026 | $20.08M | +0.6% | -0.0% | 7.6% | |
| LTM Aug 2026 | $19.76M | -5.9% | -10.9% | 2.2% | |
| LTM Jan 2026 | $19.24M | +36.6% | — | 23.0% | |
| LTM Mar 2026 | $15.36M | +17.2% | +61.5% | 5.7% | |
| LTM Mar 2026 | $8.14M | +5.5% | -20.0% | 8.2% | |
| Peer median (excluding BLFS) | $38.18M | +4.4% | +3.7% | 15.1% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 119.16M | 76.24M | 75.86M | 82.25M | 96.21M |
| Cost of Revenue | 90.31M | 29.33M | 96.52M | 28.58M | 34.1M |
| Gross Profit | 28.85M | 46.91M | 46.75M | 53.67M | 62.12M |
| Gross Margin | 24.2% | 61.5% | 61.6% | 65.3% | 64.6% |
| Research & Development | 11.82M | 14.8M | 18.8M | 7.91M | 7.57M |
| Selling, General & Admin | 48.09M | 44.93M | 55.97M | 50.15M | 55.37M |
| Operating Expenses | 73.34M | 52.83M | 117.58M | 60.8M | 74.25M |
| Depreciation & Amortization | 12.87M | 19.96M | 12.3M | 8.66M | 4.69M |
| EBITDA | (16.65M) | (124.18M) | (45.24M) | 1.53M | 3.61M |
| EBITDA Margin | -14.0% | -162.9% | -59.6% | 1.9% | 3.7% |
| Operating Income | (35.16M) | (5.92M) | (23.44M) | (7.13M) | (1.08M) |
| Operating Margin | -29.5% | -7.8% | -30.9% | -8.7% | -1.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 485K | 687K | 1.81M | 719K | 2.71M |
| Other Income / Expenses | 6.13M | 1.08M | 4.97M | (4.3M) | (11M) |
| Income Before Tax | (29.03M) | (4.85M) | (18.47M) | (11.43M) | (12.08M) |
| Pre-Tax Margin | -24.4% | -6.4% | -24.4% | -13.9% | -12.6% |
| Income Tax Expense | (20.12M) | (5.24M) | 24K | (38K) | 49K |
| Net Income | (8.91M) | (139.81M) | (66.43M) | (20.18M) | (12.13M) |
| Net Margin | -7.5% | -183.4% | -87.6% | -24.5% | -12.6% |
| EPS (Basic) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| EPS (Diluted) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| Weighted Avg Shares | 38.5M | 42.48M | 43.72M | 46.07M | 47.75M |
| Weighted Avg Shares (Diluted) | 38.5M | 42.48M | 43.72M | 46.07M | 48.65M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.